U
ARAV

UBS’s Aravive, Inc. Common Stock ARAV Stock Holding History

UBS’s Portfolio ARAV Stock Details ARAV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$334K Buy
+2,935
New +$389K ﹤0.01% 4668

Other funds holding ARAV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS's ARAV Position: Q3 2014 in Review

UBS opened a new position in Aravive, Inc. Common Stock (ARAV) in Q3 2014: 2,935 shares worth $334K. The stake represents ﹤0.01% of the portfolio and ranks #4668 among its holdings.

55 funds tracked by Wall St. Rank hold ARAV as of Q3 2014.

  • UBS held 2,935 shares of Aravive, Inc. Common Stock worth $334K as of Q3 2014.
  • Aravive, Inc. Common Stock was a new UBS position in Q3 2014.
  • Aravive, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4668 holding.
  • 55 funds tracked by Wall St. Rank held Aravive, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.